Letter
Medicine, General & Internal
Elif Hindie
Summary: The study found that treatment with teclistamab resulted in a high overall response rate of 63.0% and a median progression-free survival of 11.3 months in patients with relapsed or refractory myeloma. Additionally, the change in serum levels of soluble BCMA correlated with treatment response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Philippe Moreau, Alfred L. Garfall, Niels W. C. J. van de Donk, Hareth Nahi, Jesus F. San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun X. W. Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Nikhil C. Munshi, Larry D. Anderson, Nina Shah, Deepu Madduri, Jesus Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol, Philippe Moreau, Ibrahim Yakoub-Agha, Michel Delforge, Michele Cavo, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Alessandro Rambaldi, Donna Reece, Fabio Petrocca, Monica Massaro, Jamie N. Connarn, Shari Kaiser, Payal Patel, Liping Huang, Timothy B. Campbell, Kristen Hege, Jesus San-Miguel
Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
Philippe Moreau, Shaji K. Kumar, Jesus San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian G. M. Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele Cavo, Sigurdur Y. Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C. Anderson, Cristina Joao, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G. Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Blade, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf-Henrik Mellqvist, Dominik Dytfeld, Jean-Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksac, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria-Victoria Mateos, S. Vincent Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson
Summary: This policy review presents clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma, integrating drug access issues for patients in different income settings to improve patient outcomes in real-world practice.
Article
Medicine, General & Internal
P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis
Summary: In this study, patients with relapsed and refractory multiple myeloma received oral mezigdomide in combination with dexamethasone. The combination therapy showed promising efficacy in heavily pretreated patients with multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Immunology
Elham Roshandel, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Saeid Abroun, Reza Mirfakhraie, Abbas Hajifathali
Summary: Recent advances in adoptive cell therapy have transformed cancer immunotherapy, with a focus on treating relapsed/refractory multiple myeloma (RR/MM) using natural killer (NK) cells. NK cells exhibit effective cytotoxic activity against myeloma cells and can be derived from the patient or allogenic donors for therapy. Novel cell-based products, such as NK cell lines and CAR-NK cells, offer promising options for off-the-shelf NK cell therapy in MM.
CLINICAL IMMUNOLOGY
(2023)
Article
Oncology
Aina Oliver-Caldes, Raquel Jimenez, Marta Espanol-Rego, Maria Teresa Cibeira, Valentin Ortiz-Maldonado, Luis F. Quintana, Paola Castillo, Francesca Guijarro, Natalia Tovar, Mercedes Montoro, Daniel Benitez-Ribas, Alex Bataller, E. Azucena Gonzalez-Navarro, Joan Cid, Miquel Lozano, Lorena Perez-Amill, Beatriz Martin-Antonio, Mari-Pau Mena, David F. Moreno, Luis Gerardo Rodriguez-Lobato, Josep Maria Campistol, Gonzalo Calvo, Joan Blade, Laura Rosinol, Manel Juan, Mariona Pascal, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea
Summary: Despite being incurable, multiple myeloma may benefit from CART therapy in patients with concomitant AL amyloidosis, even when the predominant symptoms are caused by the amyloidosis itself.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Hematology
James R. R. Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin M. M. Eades, Sean Bujarski, Bernard Regidor, Clara Kim, Susanna Kim, Robert Vescio
Summary: This study evaluated the efficacy of combination therapy with ruxolitinib and methylprednisolone for multiple myeloma patients. The results showed that this treatment regimen demonstrated significant clinical activity among heavily-treated patients and achieved responses in patients with high-risk cytogenetics.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesus Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre-Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
Summary: In this international phase 3 trial, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, was found to significantly prolong progression-free survival and improve response compared to standard regimens in patients with relapsed and refractory multiple myeloma. The toxicity of ide-cel was consistent with previous reports.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Boris Bozic, Jens Rutner, Chang Zheng, Reinhard Ruckser, Flonza Selimi, Krysztina Racz, Martin Koecher, Georg Tatzreiter, Christian Sebesta
Summary: The treatment of patients with relapsed/refractory multiple myeloma and renal impairment is more complex compared to those with normal renal function, primarily due to the toxic effects of monoclonal light chains on the kidneys necessitating dose adjustments for effectiveness. Renal impairment is a frequent complication in multiple myeloma patients, with interdisciplinary approaches involving hematologist-oncologists, radiologists, nephrologists, and intensive care specialists being crucial for diagnosis and treatment. The use of new drugs, such as carfilzomib, panobinostat, elotuzumab, pomalidomide, or daratumumab, has shown significant improvements in progression-free survival and overall survival in these patients.
Review
Oncology
Klaus Podar, Xavier Leleu
Summary: Collaborative translational studies have enhanced our knowledge of multiple myeloma pathophysiology over the past two decades, but it remains an incurable disease requiring ongoing research to improve patient outcomes. Exciting therapeutic progress, including new drug approvals and emerging treatments in 2020/2021, continues to advance in the field of multiple myeloma.
Article
Oncology
Paul G. Richardson, Albert Oriol, Alessandra Larocca, Joan Blade, Michele Cavo, Paula Rodriguez-Otero, Xavier Leleu, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrian Alegre, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Jan S. Moreb, Kenneth C. Anderson, Jacob P. Laubach, Sara Thuresson, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A. Bakker, Maria-Victoria Mateos
Summary: The combination of Melphalan flufenamide (melflufen) and dexamethasone showed significant efficacy and manageable safety profile in patients with heavily pretreated relapsed and refractory multiple myeloma (RRMM), including those with triple-class-refractory disease and extramedullary disease.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Poornima Sharma, Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu, Wilson W. Bryan, Richard Pazdur, Marc R. Theoret
Summary: In March 2021, the FDA approved a new treatment for adult patients with relapsed/refractory multiple myeloma. The treatment showed a high overall response rate and complete response rate, with a prolonged duration of response. However, there were also serious adverse reactions and potential risks associated with the treatment.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Josh N. Vo, Yi-Mi Wu, Jeanmarie Mishler, Sarah Hall, Rahul Mannan, Lisha Wang, Yu Ning, Jin Zhou, Alexander C. Hopkins, James C. Estill, Wallace K. B. Chan, Jennifer Yesil, Xuhong Cao, Arvind Rao, Alexander Tsodikov, Moshe Talpaz, Craig E. Cole, Jing C. Ye, P. Leif Bergsagel, Daniel Auclair, Hearn Jay Cho, Dan R. Robinson, Arul M. Chinnaiyan
Summary: In this study, genomic and transcriptomic profiling of 511 relapsed and refractory multiple myeloma (MM) patients revealed genetic alterations in several oncogenic pathways contributing to disease progression and resistance to MM therapies.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Shansa Pranami E. Jayaweera, Sacheela Prasadi Wanigasinghe Kanakanamge, Dharshika Rajalingam, Gayathri N. Silva
Summary: The proteasome plays a crucial role in regulating key regulatory proteins in cells, especially in tumor cells. Proteasome inhibitors have been proven effective in treating multiple myeloma, with carfilzomib being a second-generation inhibitor that overcomes toxicities and resistance associated with previous drugs.
FRONTIERS IN ONCOLOGY
(2021)